Bloomberg News, June 15, 2023: If Leqembi is approved, it will take time for doctors to arrange for patients to be tested for mild cognitive impairment and amyloid plaques on the brain, get the Leqembi infusions, and sign up patients for a registry. NCHR praises the CMS Registry as a good choice, but industry-funded groups complain.
Read More »Medical Care for Adults
The National Center for Health Research reviews important new research as soon as it is published. We cut through the hype regarding various medical treatments to let you know what is proven and what is unknown about the risks and benefits of various treatment options. We do not accept funding from the companies that make medical products, so you can trust that our information is based on science, and not biased by financial ties to the treatments we’re evaluating.
To find the information you need, please use our search box to search for exactly what you are looking for or browse through our various topics on the right. →
Some of these articles were written this year and others were not, however, if they are on our website it means the information is up-to-date. We always scrutinize new research and call the researchers to learn even more. Then we translate it into plain language that everyone can understand.
If you’re looking for more detailed information about cancer, please go to our Cancer Prevention and Treatment website.
If you don’t see what you are looking for on any health topic, please contact us and we will try to get the information you need within a few days.
US FDA adcom supports Leqembi for full approval
BioWorld, June 9, 2023: BioWorld news explains that FDA Advisory Committee supports Leqembi for Mild Cognitive Impairment (MCI) caused by Alzheimer’s and quotes our statement that MCI can go away without drugs, which means that Leqembi’s risks of brain swelling and bleeding will often greatly outweigh the potential benefits.
Read More »NCHR Comments on the Filing of Color Additive Petition to FDA from the Center for Science in the Public Interest
May 18, 2023: We support the request that the FDA ban the use of FD&C Red No. 3 in foods, drugs, and dietary supplements. We find it unacceptable that the FDA has known for more than 30 years that Red 3 can cause cancer and yet still allows the dye to be used in foods, drugs, and supplements.
Read More »EPA Public Meeting on Proposed Rule to Reduce PFAS in Water
May 4, 2023: We provided a public comment at an EPA public meeting to support their proposed rule to reduce PFAS in water and suggested ways to strengthen the rule to save more lives by reducing limits on these carcinogenic chemicals.
Read More »NCHR Comment on USPSTF Draft Research Plan on Interventions to Prevent Perinatal Depression
We appreciate efforts by the US Preventive Services Task Force to reduce perinatal depression, which is one of the most common complications of pregnancy. Perinatal depression contributes significantly to maternal mortality and adverse neonatal, infant, and child outcomes. We agree that developing effective interventions to prevent perinatal depression is essential to reduce the U.S. maternal mortality rate.
Read More »